Novartis is acquiring Anthos Therapeutics for up to $3.08 billion, adding abelacimab, a late-stage anticoagulant, to its ...

Under the terms of the agreement, Novartis will pay $925 million upfront and up to $2.15 billion, contingent upon achievement ...

Novartis was among the most prolific pharma dealmakers in 2024, a trend that it expects to continue with more bolt-on deals ...

Novartis has reached an agreement to take control of Kate Therapeutics, a developer of gene therapies for inherited neuromuscular diseases, including Duchenne muscular dystrophy (DMD). The ...

In November, San Diego biotech Kate Therapeutics announced that it would be acquired by pharmaceutical giant Novartis for approximately $1 billion. The Kate acquisition was the third largest exit ...